Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 40 years of age and no older than 80 at Visit 1.~* Women of non-child bearing potential,or negative serum pregnancy test at Screening, and agrees to acceptable contraceptive methods used consistently and correctly from Screening until 14 days after final visit~* Evidence of lung hyperinflation~* Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)~* Current or former smokers with a history of at least 10 pack-years of cigarette smoking.~* Pre- and Post-bronchodilator FEV1/FVC ratio must be \<0.70~* Post-bronchodilator FEV1 must be ≥30% to \<65% predicted normal value, calculated using NHANES III reference equations.~Exclusion Criteria:~* Significant diseases or conditions other than COPD which, in the opinion of the Investigator, may put the patient at risk~* Women who are pregnant or lactating or are planning to become pregnant during the course of the study~* Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma or other active pulmonary disease~* Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening~* Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Screening or during the Screening Period~* Subjects who have clinically significant uncontrolled hypertension.~* Subjects with symptomatic prostatic hypertrophy that is clinically significant and not adequately controlled with appropriate therapy, in the opinion of the Investigator.~* Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator.~* Subjects with a calculated creatinine clearance ≤30 mL/minute using Chronic Kidney Disease Epidemiology Collaboration. (CKD-EPI) formula at Screening and on repeat testing prior to Visit 2.~* Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times upper limit of normal at Screening and on repeat testing prior to Visit 2~* Subjects who have cancer that has not been in complete remission for at least five years.~* Subjects with a diagnosis of glaucoma, who in the opinion of the Investigator, have not been adequately treated.~* Subjects with a clinically significant ECG~* Subjects who were previously enrolled in any previous PT001, PT003, or PT005 study conducted or sponsored by Pearl.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GFF MDI (PT003) (Type: EXPERIMENTAL): Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

Based on this trial design, predict the completion outcome and termination type (if applicable).